<DOC>
	<DOC>NCT00268177</DOC>
	<brief_summary>This study was designed to look at effects of salmeterol/fluticasone propionate compared to placebo on airway inflammation in patients with chronic obstructive airways disease</brief_summary>
	<brief_title>Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Established clinical history of chronic obstructive airways disease. Must be current or exsmokers with a smoking history of at least 10 packyears (e.g. 20 cigarettes/day for 10 years or 10 cigarettes/day for 20 years). Must have reduced lung function, defined as a Forced Expiratory Volume in 1 second (FEV1) of between 4080% of predicted normal values. Diagnosis of any other serious disease and must have a chest Xray to eliminate a diagnosis other than COPD.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Airways</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Obstructive</keyword>
	<keyword>Chronic</keyword>
	<keyword>inflammation</keyword>
	<keyword>salmeterol/fluticasone propionate</keyword>
</DOC>